In the future, visiting the doctor could mean getting a genetic test, and in return receiving medication that is tailored to you, precisely. No longer would the physician have to put much guesswork into what drugs to prescribe and in what dose. Instead, she could prescribe treatments based on a precise diagnosis of your exact condition, having a good idea in advance how you would react to certain drugs.
This is the promise of personalized medicine, and it is one that has tantalized doctors and scientists since the human genome was sequenced in 2000.
Throughout the pharmaceutical industry, researchers are laying the groundwork to make the promise of better and cheaper healthcare through personalized medicine a reality.
The BioNJ trade association is bringing together world leaders in the field of personalized medicine for a summit Thursday, June 6, from 8:30 a.m. to 4:30 p.m. at Sanofi, 55 Corporate Drive in Bridgewater. To register, visit www.bionj.com or call 609-890-3185. The fee is $75 for BioNJ members, $110 for non-members. The first such gathering took place last year.
Keynote speakers at the Personalized Medicine Innovation Summit include leaders from global life sciences companies as well as the investment community, including Elias Zerhouni, president of global R&D for Sanofi, and G. Steven Burrill, CEO of Burrill & Co.
In addition to keynote speakers, the agenda includes a series of moderated interactive panel discussions focused on research and commercialization challenges in diagnostics and personalized medicine.
